Is compounded GLP-1 legal in 2026?

What 503A allows, and what it doesn’t

Section 503A covers a drug “compounded for an identified individual patient based on the receipt of a valid prescription order,” prepared by a licensed pharmacist in a state-licensed pharmacy (21 U.S.C. 353a). Three limits matter for GLP-1 medicines:

• Prescription first. Each preparation is for one identified patient with a valid prescription.
• No regular copies. A 503A pharmacy may not compound “regularly or in inordinate amounts” products that are “essentially copies” of a commercially available drug.
• The clinical-difference exception. A preparation is not a copy when a change made for that patient produces “a significant difference, as determined by the prescribing practitioner.”

FDA’s 2018 guidance on “essentially copies” adds that the prescription should record the change and why the patient needs it, and that “a lower price” is not enough to make a preparation something other than a copy. 503A pharmacies are not held to the manufacturing-quality rules (CGMP) that drug makers follow (FDA Q&A).

Section 503B is different: outsourcing facilities register with FDA, follow CGMP and may compound without a patient-specific prescription, but may not make copies of approved drugs outside a shortage.

What changed when the shortages ended

While a drug is on FDA’s shortage list, it is not considered “commercially available,” so the copies limit does not apply (FDA). FDA has since found both shortages resolved, and the extra time it gave compounders has ended:

What regulators have done in 2025–2026

• Warning letters in three waves (September 2025, March 2026 and June 2026) to telehealth companies marketing compounded GLP-1s. FDA objected to marketing that presents a compounded drug as interchangeable with an approved drug or as backed by that drug’s trials, and to branding that suggests the telehealth company makes the drug. FDA also says it “does not approve or license any facility” (FDA, March 2026; FDA guidance to telehealth companies).
• An import “green list” for GLP-1 ingredients (September 5, 2025): active ingredients from facilities FDA has not inspected or evaluated can be detained at the border (FDA).
• A statement on mass-marketed compounded GLP-1s (February 6, 2026): FDA said it intends to restrict GLP-1 ingredients meant for compounded drugs that are mass-marketed as similar alternatives to approved drugs (FDA).
• A proposal on 503B bulk substances (April 30, 2026): FDA proposed not adding semaglutide, tirzepatide or liraglutide to the 503B bulks list. It is a proposal, and it covers 503B outsourcing facilities only (FDA; Federal Register).
• States can be stricter. California’s pharmacy rules (effective October 1, 2025) require the pharmacist to verify and document a clinically significant difference for the patient (California Board of Pharmacy); Ohio’s board said on July 17, 2025 that semaglutide and tirzepatide can no longer be compounded as copies (Ohio Board of Pharmacy). Rules vary by state and change often.
• Bills in Congress. S. 3794 was reported by a Senate committee on July 27, 2026. It is not law (GovInfo).

What FDA says about risks

FDA’s page on unapproved GLP-1 drugs (content current as of September 1, 2026) says compounded drugs are not FDA-approved, so the agency does not review them for safety, effectiveness or quality before they are marketed. It says a compounded drug might be appropriate if a patient’s medical need cannot be met by an FDA-approved drug.

As of May 31, 2026, FDA had received 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. A report alone does not show that a medicine caused the problem. FDA also describes dosing errors, some leading to hospital care, often from confusion between milliliters, milligrams and “units” (FDA alert), and warns about counterfeit products and labels that name pharmacies that do not exist.

FDA’s advice to patients: get a prescription from a licensed clinician, use a state-licensed pharmacy, and report problems to MedWatch.

What REMEVi’s program includes

• A clinician licensed in your state reviews your health history and decides whether a prescription is appropriate. A prescription is never guaranteed.
• A named, state-licensed 503A pharmacy fills an individual prescription. See the pharmacies.
• Compounded medications are not FDA-approved.
• REMEVi is LegitScript-certified (ID 50384507; check it).
• The program is available in 49 states and Washington, DC. REMEVi’s clinical network does not prescribe compounded GLP-1 medications to patients in Louisiana. Where we treat.

Common questions

Sources

1. 21 U.S.C. 353a (section 503A) · statute text, no page date
2. FDA, Compounding and the FDA: Questions and Answers · content current as of 09/16/2025
3. FDA guidance, Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A · final guidance, January 2018
4. FDA, Compounding when drugs are on FDA’s drug shortages list · last updated 08/08/2025
5. FDA declaratory order, tirzepatide · FDA declaratory order, December 19, 2024
6. FDA declaratory order, semaglutide · FDA declaratory order, February 21, 2025
7. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize · accessed September 23, 2026
8. Outsourcing Facilities Association v. FDA (5th Cir.), tirzepatide · No. 25-10600, filed August 27, 2026
9. Outsourcing Facilities Association v. FDA (5th Cir.), semaglutide · No. 25-10758, filed August 27, 2026
10. FDA launches “green list” for imported GLP-1 ingredients · content current as of 09/05/2025
11. FDA intends to take action against non-FDA-approved GLP-1 drugs · content current as of 02/06/2026
12. FDA warns 30 telehealth companies about compounded GLP-1 marketing · content current as of 03/03/2026
13. FDA to telehealth companies: what to know when promoting compounded drugs · content current as of 06/15/2026
14. FDA proposes to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list · content current as of 04/30/2026
15. Federal Register notice, 503B bulk drug substances (Docket FDA-2018-N-3240) · 91 FR 23431, May 1, 2026
16. California Board of Pharmacy, compounding regulations · order of adoption; effective October 1, 2025
17. Ohio Board of Pharmacy, compounding of GLP-1 drug products · July 17, 2025
18. S. 3794, 119th Congress (reported in the Senate) · reported in the Senate July 27, 2026
19. FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of 09/01/2026
20. FDA alert on dosing errors with compounded injectable semaglutide · July 26, 2024

This page is general information, not legal advice.